Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Group 1 - The article reports on the dividend distribution announcements from three A-share listed companies: Heshun Petroleum, Southwest Securities, and Sanyuan Bio, with specific payout details provided [1] - Heshun Petroleum will distribute a dividend of 1.00 yuan per 10 shares (after tax 0.90 yuan) [1] - Southwest Securities will distribute a dividend of 0.10 yuan per 10 shares (after tax 0.09 yuan) [1] - Sanyuan Bio will distribute a dividend of 5.00 yuan per 10 shares (after tax 4.50 yuan) [1] Group 2 - The article lists several companies with their respective dividend record dates, including Guangzhou Restaurant, Fujian Expressway, New Media Co., Runhe Software, Huangshan Capsule, Province Advertising Group, and Suihengyun A [1] - Guangzhou Restaurant will have a record date for a dividend of 1.00 yuan per 10 shares (after tax 0.90 yuan) [1] - Fujian Expressway will have a record date for a dividend of 0.50 yuan per 10 shares (after tax 0.45 yuan) [1] - New Media Co. will have a record date for a dividend of 11.00 yuan per 10 shares (after tax 9.90 yuan) [1] - Runhe Software will have a record date for a dividend of 0.70 yuan per 10 shares (after tax 0.63 yuan) [1] - Huangshan Capsule will have a record date for a dividend of 0.33 yuan per 10 shares (after tax 0.297 yuan) [1] - Province Advertising Group will have a record date for a dividend of 0.11 yuan per 10 shares (after tax 0.099 yuan) [1] - Suihengyun A will have a record date for a dividend of 0.60 yuan per 10 shares (after tax 0.54 yuan) [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大 遗漏。 一、股东会审议通过利润分配方案的情况 1. 安徽黄山胶囊股份有限公司（以下简称"公司"或"本公司"）于2025年12月18日召开2025年第一次临时 股东会，审议通过《关于公司2025年前三季度利润分配预案的议案》，具体内容如下： 以公司现有总股本299,098,170股为基数，向全体股东每10股派发现金红利人民币0.33元（含税），合计 派发现金红利人民币9,870,239.61元（含税）； 2.自分配方案披露至实施期间公司股本总额未发生变化，若本次分配方案披露至实施期间，公司总股本 发生变化，将按照分配总额固定的原则实施； 3.本次实施的分配方案与公司2025年第一次临时股东会审议通过的分配方案一致； 4.本次实施分配方案距离股东会审议通过的时间未超过两个月。 二、本次实施的利润分配方案 本次权益分派股权登记日为：2025年12月30日，除权除息日为：2025年12月31日。 四、分红派息对象 本次分派对象为：截止2025年12月30日下午深圳证券交易所收市 ...

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：小讯 本次权益分派股权登记日为：2025年12月30日，除权除息日为：2025年12月31日。 格隆汇12月23日丨黄山胶囊(002817.SZ)发布2025年前三季度权益分派实施公告，以公司现有总股本 299,098,170股为基数，向全体股东每10股派0.330000元人民币现金（含税；扣税后，通过深股通持有股 份的香港市场投资者、境外机构（含QFII、RQFII）以及持有首发前限售股的个人和证券投资基金每10 股派0.297000元）。 ...

南财智讯12月23日电，黄山胶囊发布2025年前三季度分红派息实施公告，公司以现有总股本为基数，向 全体股东每10股派0.33元人民币现金（含税），本次权益分派股权登记日为2025年12月30日，除权除息 日为2025年12月31日。现金红利将于2025年12月31日通过股东托管证券公司直接划入资金账户。 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-041 安徽黄山胶囊股份有限公司 2025 年前三季度分红派息实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、股东会审议通过利润分配方案的情况 本公司 2025 年前三季度权益分派方案为：以公司现有总股本 299,098,170 股为基数，向全体股东每 10 股派 0.330000 元人民币现金（含税；扣税后，通过 深股通持有股份的香港市场投资者、境外机构（含 QFII、RQFII）以及持有首发 前限售股的个人和证券投资基金每 10 股派 0.297000 元；持有首发后限售股、股 权激励限售股及无限售流通股的个人股息红利税实行差别化税率征收，本公司暂 不扣缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额【注】； 持有首发后限售股、股权激励限售股及无限售流通股的证券投资基金所涉红利税， 对香港投资者持有基金份额部分按 10%征收，对内地投资者持有基金份额部分实 行差别化税率征收），【注：根据先进先出的原则，以投资者证券账户为单位计 算持股期限，持股 1 个月（含 1 个月 ...

证券日报网讯12月18日晚间，黄山胶囊（002817）发布公告称，公司聘任楚振华先生、范剑先生、张文 政先生为副总经理。 ...

证券日报网讯12月18日晚间，黄山胶囊（002817）发布公告称，公司聘任董雪女士为审计部经理。 ...

证券日报网讯 12月18日晚间，黄山胶囊（002817）发布公告称，公司聘任刘清科先生为财务总监。 ...

证券日报网讯 12月18日晚间，黄山胶囊（002817）发布公告称，公司聘任叶松林先生为总经理。 ...